GlassScriptPhysician profile
Joshua Lee
NPI 1114132701
$1,485.58
in general payments reported to CMS, 2019-2025
16 companies · $386 in 2025
The $386 reported for 2025 was more than what 75% of Addiction Medicine (Internal Medicine) providers received nationally (typical 2025 total: $124).
See the full distribution for Addiction Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $120 · 2021: $127 · 2022: $73.21 · 2023: $277 · 2024: $354 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,016.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $398.44 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $270.16 | 2021-2025 | Ofev, Jascayd, Spiriva Respimat |
| Glaxosmithkline, LLC. | $149.62 | 2020-2025 | Nucala |
| Alphatec Spine, INC | $144.25 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2019 | |
| Medline Industries LP | $110.43 | 2024-2025 | Medline |
| Takeda Pharmaceuticals U.S.A., INC. | $110.23 | 2020-2025 | Glassia, Aralast |
| Janssen Pharmaceuticals, INC | $46.43 | 2022-2023 | Xarelto |
| Jazz Pharmaceuticals INC. | $35.75 | 2019-2020 | |
| Invivyd INC | $29.50 | 2025 | Pemgarda |
| Janssen Biotech, INC. | $23.59 | 2025 | Tremfya |
| Teva Pharmaceuticals USA, INC. | $15.59 | 2020 | |
| Mylan Specialty L.P. | $14.55 | 2020 | |
| Merck Sharp & Dohme LLC | $12.04 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.